Anagram Therapeutics is dedicated to developing innovative orally-delivered enzyme therapeutics aimed at treating rare and life-threatening diseases, particularly those related to malabsorption syndromes and nutrient metabolism disorders. These conditions arise from enzyme deficiencies or genetic mutations that hinder the body's ability to metabolize essential nutrients, leading to severe health consequences such as debilitating gastrointestinal symptoms, weight loss, and increased morbidity. Anagram's mission is to transform the treatment landscape for these disorders by leveraging their expertise in enzyme science and gastrointestinal physiology to create breakthrough therapies that can significantly improve the quality of life for affected individuals.

The company is advancing a robust pipeline of enzyme therapies designed to address specific malabsorption issues. Their candidates, such as ANG003, ANG011, ANG021, and ANG031, are engineered to provide targeted solutions for various conditions, including exocrine pancreatic insufficiency and congenital malabsorptive syndromes. By focusing on the development of a new class of enzyme replacement therapies with broad-spectrum compositions, Anagram aims to deliver unparalleled performance in treating these complex disorders. Their commitment to scientific innovation and patient-centered solutions positions Anagram as a leader in the biopharmaceutical industry, dedicated to making a meaningful impact on the lives of those affected by these challenging health issues.

United States

Anagram is a clinical stage company leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. Malabsorption syndromes and nutrient metabolism disorders prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. ANG003, Anagram’s lead product is intended for the treatment of malabsorption and exocrine pancreatic insufficiency and is a new class of broad-spectrum digestive enzyme replacement therapy.
 

Anagram

Company Details